CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2006-03-03): Interferon protein predicts hepatitis C response

Clinical

Interferon protein predicts hepatitis C response

Last Updated: 2006-03-03 15:53:45 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Pretreatment levels of interferon gamma inducible protein 10 (IP-10) are associated with sustained virological response of hepatitis C to treatment with peginterferon and ribavirin, according to a report in the March issue of Gut.

"Genotype 1-infected patients with low serum IP-10 levels before therapy have a higher probability of response to antiviral therapy than those with elevated IP-10 concentrations," Dr. Carmelo Garcia-Monzon from University Hospital Santa Cristina, Madrid, told Reuters Health.

Dr. Garcia-Monzon and colleagues evaluated the relationship between pretreatment serum IP-10 levels and the virological response to peginterferon plus ribavirin therapy in 137 patients chronically infected with hepatitis C virus.

Seventy-nine of the patients (57.7%) achieved a sustained virological response, the authors report, and 58 patients (42.3%) were nonresponders.

In a multivariate logistic regression analysis of all patients, only non-1 genotype and low baseline viral load were independent predictors of a sustained virological response.

When only patients infected with genotype 1 were considered, pretreatment IP-10 levels and baseline viral load were independent predictors of a sustained virological response.

Among all hepatitis C virus-infected patients, those with a sustained virological response had significantly lower pretreatment serum IP-10 levels than the nonresponders, the report indicates, but there was no significant difference in serum IP-10 levels between the groups after 12 weeks of treatment.

Pretreatment IP-10 levels were significantly higher in patients with genotype 1 or with advanced fibrosis, the researchers note, but there was no association between pretreatment IP-10 levels and sex, viral load, or grade of necroinflammatory activity from the pretreatment liver biopsy.

"Based on our results, IP-10 may have a role in failure of antiviral therapy in patients with chronic HCV infection," the investigators suggest. "However, the mechanism by which IP-10 modulates the efficacy of peginterferon plus ribavirin therapy remains elusive, but it is conceivable that it is related to its biological functions."

"Our clinical results suggest that IP-10 might interfere with antiviral activity of interferon alpha in the liver," Dr. Garcia-Monzon said. "We are planning to carry out studies on cultured hepatocytes in order to determine whether IP-10 modulates interferon-mediated antiviral response. Understanding the molecular basis of IP-10 effects on target cells could provide strategies for improving the antiviral therapy in chronic HCV infection."

"Predicting response to antiviral therapy is a crucial point in the management of patients with chronic HCV infection," Dr. Garcia-Monzon concluded. "We have shown that IP-10 could be important for optimizing therapy in genotype 1 patients who are the most difficult to cure. Definitive conclusions on this issue, however, must await validation studies worldwide."

Gut 2006;55:374-379.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.